2024-12-25 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a multinational healthcare company, significantly underperformed the S&P 500 (VOO) over the period analyzed.  The cumulative return of JNJ is 24.19%, while VOO's is 117.56%.  This represents a difference of -93.4%, placing it at the 4.6th percentile of its historical range of divergence from the S&P 500 (-98.8% to 17.7%).  The provided alpha values consistently hover around zero, indicating that JNJ's performance is largely explained by its beta (market sensitivity). The beta values are not consistently provided.

**2. Recent Price Movement:**

* **Closing Price:** $145.27
* **Last Market Price:** $145.85
* **5-day Moving Average:** $144.90
* **20-day Moving Average:** $149.13
* **60-day Moving Average:** $155.05

The price is below all three moving averages, suggesting a downtrend.  The last market price of $145.85 is not significantly different enough to suggest a sharp upward or downward movement.

**3. Technical Indicators and Expected Return:**

* **RSI (29.06):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.15):**  Shows negative momentum, aligning with the price action.
* **Relative Strength (20-day):**  A positive change of +4.6 suggests a recent short-term upward trend.
* **Expected Return (2+ years):** 0.0%. This suggests that, based on the provided data, long-term investment in JNJ is not expected to significantly outperform the S&P 500.

**4. Recent Earnings Analysis:**

The provided earnings data reveals a fluctuating EPS and relatively stable revenue:

* **Revenue:** Revenue has remained relatively consistent, hovering around $21-22.5B for the past few quarters with minor fluctuations.  There isn't a clear upward or downward trend.
* **EPS:** EPS fluctuates significantly between quarters (1.12 to 10.32), making it difficult to establish a clear trend without further context (e.g., one-time events). The exceptionally high EPS in Q3 2023 warrants further investigation to understand the underlying drivers.  Without further context, it's impossible to assess whether these results beat or missed expectations.

**5. Financial Information:**

* **Revenue and Profitability:** Revenue has been consistently high. Profit margins are generally stable and high, ranging from 68.23% to 69.55%, indicating strong profitability.
* **Capital and Profitability:** Equity fluctuates, and ROE shows considerable volatility.  The exceptionally high ROE of 36.54% in Q3 2023 is an outlier and needs further investigation to understand the contributing factors.

**6. News and Recent Issues:**

No recent (within 2 days) earnings news or analyst opinions are provided.  Information regarding the market outlook is missing.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the analyzed period. While the recent price action shows some signs of short-term upward momentum (RSI near oversold territory, positive relative strength change), the long-term outlook based on provided data remains uncertain. The high volatility in EPS and ROE raises concerns requiring further investigation. Stable revenue and consistently high-profit margins are positive indicators, but the overall picture is clouded by the significant underperformance relative to the market and inconsistent earnings. More information is needed to form a definitive conclusion, particularly regarding the unusual EPS and ROE figures for Q3 2023.  The lack of recent news and market outlook data limits a comprehensive assessment.

**8. Recommendations:**

Given the limited data and inconsistencies, a strong buy or sell recommendation cannot be made.  Further research is necessary to understand the drivers behind the volatile EPS and ROE, the lack of market outperformance, and to gain perspective from recent news and analyst reports.  Investors should carefully consider the risks associated with JNJ before making any investment decisions.  The provided data points to a need for more detailed analysis to determine if the current valuation appropriately reflects its fundamentals and future prospects.
